Krystal Biotech Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Krystal Biotech, Inc. (KRYS) - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Operating Activities
Net Income89.1610.93-139.98-69.57-32.17
Depreciation & Amortization6.715.913.392.771.85
Stock Based Compensation49.1339.9333.2315.323.27
Change in Working Capital-14.46-38.522.662.510.92
Change in Accounts Receivable-62.71-42.040.000.000.00
Change in Inventory-11.91-4.480.000.000.00
Change in Accounts Payable1.01-0.10-1.250.710.78
Change in Other Working Capital59.150.220.031.790.13
Other Operating Activities-7.120.220.031.040.01
Net Cash from Operating Activities123.42-88.80-100.57-47.94-26.08
Investing Activities
Capital Expenditures-4.24-11.80-52.98-68.34-14.84
Purchases of Investments-457.74-508.78-318.78-158.433.66
Sales/Maturities of Investments298.54503.21257.6832.030.00
Net Cash from Investing Activities-163.4482.64-114.08-226.77-11.18
Financing Activities
Common Stock Issued32.40159.7328.99355.65118.02
Common Stock Repurchased0.00-0.75-0.650.000.00
Other Financing Activities-5.39-0.75-0.65-7.960.00
Net Cash from Financing Activities27.01202.7535.35347.69118.02
Summary
Effect of Forex Changes on Cash-0.46-0.16-0.040.000.00
Net Change in Cash-13.46196.58-179.3172.9880.76
Cash at Beginning of Period358.33161.90341.25268.270.00
Cash at End of Period344.87358.33161.90341.250.00
Free Cash Flow119.18-100.60-153.55-116.27-40.93
Supplemental Disclosures
Income Taxes Paid5.670.000.000.000.00